Oncompass Medicine, based in Budapest, is a leading brand in the field of precision oncology. Their Precision Oncology Program offers a comprehensive range of services aimed at selecting the most appropriate personalized treatment for cancer patients. This program is supported by advanced medical software developed by Oncompass.

The process begins with a consultation, during which various factors are considered, including clinical data, previous molecular diagnostic results, and patient needs and options. The next step is the Tumor Board, which consists of experts in clinical oncology, genetics, molecular biology, and diagnostics. They determine the necessary molecular diagnostic tests tailored to each patient's case.

Sample logistics and quality checks ensure that the tissue sample is suitable for testing. Molecular diagnostics then identify the genetic defects causing the disease. This detailed genetic profiling helps in making the right therapeutic decisions.

Oncompass Medicine's award-winning AI-based software is used for digital therapy planning, allowing for personalized treatment and immunotherapy planning. The software evaluates and prioritizes treatment options within milliseconds based on extensive scientific evidence. The final step involves the Molecular Tumor Board, which summarizes personalized treatment options for each case, including registered drugs and compounds under development.

The Precision Oncology Opinion provides expert guidance, and Oncompass also offers support for accessing off-label treatments and clinical trials through their Therapy Access Program. With their dedication to precision oncology and state-of-the-art technology, Oncompass Medicine is committed to revolutionizing cancer treatment and improving patient outcomes